FRTX vs. PALI, CHRO, FNCH, CELZ, TTNP, TCON, KRBP, GMDAQ, ALBT, and SRNE
Should you be buying Fresh Tracks Therapeutics stock or one of its competitors? The main competitors of Fresh Tracks Therapeutics include Palisade Bio (PALI), Chromocell Therapeutics (CHRO), Finch Therapeutics Group (FNCH), Creative Medical Technology (CELZ), Titan Pharmaceuticals (TTNP), TRACON Pharmaceuticals (TCON), Kiromic BioPharma (KRBP), Gamida Cell (GMDAQ), Avalon GloboCare (ALBT), and Sorrento Therapeutics (SRNE). These companies are all part of the "medical" sector.
Fresh Tracks Therapeutics (NASDAQ:FRTX) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends, community ranking and analyst recommendations.
Fresh Tracks Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.
Fresh Tracks Therapeutics has higher revenue and earnings than Palisade Bio. Fresh Tracks Therapeutics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.
25.0% of Fresh Tracks Therapeutics shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 0.2% of Fresh Tracks Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Palisade Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Palisade Bio had 5 more articles in the media than Fresh Tracks Therapeutics. MarketBeat recorded 7 mentions for Palisade Bio and 2 mentions for Fresh Tracks Therapeutics. Fresh Tracks Therapeutics' average media sentiment score of 0.66 beat Palisade Bio's score of -0.13 indicating that Fresh Tracks Therapeutics is being referred to more favorably in the media.
Palisade Bio received 7 more outperform votes than Fresh Tracks Therapeutics when rated by MarketBeat users. Likewise, 41.18% of users gave Palisade Bio an outperform vote while only 0.00% of users gave Fresh Tracks Therapeutics an outperform vote.
Palisade Bio has a net margin of 0.00% compared to Fresh Tracks Therapeutics' net margin of -91.29%. Fresh Tracks Therapeutics' return on equity of -60.83% beat Palisade Bio's return on equity.
Palisade Bio has a consensus price target of $131.25, suggesting a potential upside of 2,069.42%. Given Palisade Bio's higher possible upside, analysts clearly believe Palisade Bio is more favorable than Fresh Tracks Therapeutics.
Summary
Palisade Bio beats Fresh Tracks Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Fresh Tracks Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fresh Tracks Therapeutics Competitors List
Related Companies and Tools
